Improving cancer mutation detection through advanced sequencing techniques
Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations
This study is working on improving a special testing method to find tiny amounts of cancer-related genetic changes, which can help doctors make better treatment choices for patients, especially in tracking how well treatments are working and spotting any drug resistance.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10870068 on NIH RePORTER |
What this research studies
This research focuses on enhancing next-generation sequencing (NGS) methods to accurately detect and quantify cancer-related genetic mutations at very low levels. By developing a cost-effective and scalable approach, the research aims to identify critical markers that can inform treatment decisions in precision medicine. The methodology involves error correction techniques that improve the reliability of sequencing results, making it possible to detect drug-resistance mutations and residual cancer cells after therapy. This could lead to earlier cancer detection and better monitoring of treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who require precise genetic testing to guide their treatment plans.
Not a fit: Patients with non-cancerous conditions or those who do not require genetic testing for their treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the accuracy of cancer mutation detection, leading to more personalized and effective treatment options for patients.
How similar studies have performed: Previous research has shown promise in improving sequencing accuracy, suggesting that this approach could lead to significant advancements in cancer detection and treatment.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Salipante, Stephen J — University of Washington
- Study coordinator: Salipante, Stephen J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.